In non-small cell lung cancer, FTO has been demonstrated to enhance tumor proliferation through multiple m6A-dependent mechanisms, including activation of KRAS signaling and upregulation of USP7 and MZF1 [48]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.